CJC-1295 & GHRP-2 & Ipamorelin Blend
A triple GH-stimulating research blend combining CJC-1295 with both GHRP-2 and ipamorelin for comprehensive GHS-R1a activation alongside GHRHR stimulation.
Community Rating
No ratings yet
⚠ Research & Educational Use Only. CJC-1295 & GHRP-2 & Ipamorelin Blend is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Triple mechanism: GHRHR + dual GHS-R1a stimulation
- GHRP-2 for potency + ipamorelin for selectivity
- Strong GH pulse amplitude with partial selectivity benefit
- CJC-1295 & GHRP-2 & Ipamorelin Blend is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Triple mechanism: GHRHR + dual GHS-R1a stimulation
- GHRP-2 for potency + ipamorelin for selectivity
- Strong GH pulse amplitude with partial selectivity benefit
- Comprehensive GH axis research protocol
What is CJC-1295 & GHRP-2 & Ipamorelin Blend?
Tap any underlined term for an instant definition.
CJC-1295 & GHRP-2 & Ipamorelin Triple Blend combines a GHRH analogue with two GHSPs of complementary properties: GHRP-2 (high potency) and ipamorelin (high selectivity). The rationale is that lower doses of each GHRP, combined rather than used alone, can produce high GH output while limiting the cortisol/prolactin side effects associated with high-dose GHRP-2.
What It Is
- CJC-1295 (no DAC): GHRHR activation
- GHRP-2 at reduced dose: high GH-stimulating potency without full side-effect burden
- Ipamorelin at reduced dose: adds selectivity and independent GHS-R1a pathway coverage
- Combined for comprehensive GH axis stimulation with partial side effect mitigation
How It Works
- Three-way synergistic GH release: GHRHR + two independent GHS-R1a stimuli
- The dual-GHRP approach may produce additive GHS-R1a signaling above single-GHRP protocols
- Lower individual GHRP doses reduce cortisol/prolactin while maintaining high total GH output
Research Basis
- Each component has documented individual GH-stimulating activity
- The combination is a logical extension of the well-characterized GHRH + single GHRP synergy
- Dose titration of each component required for optimal individual response
Dosing From the Literature
- CJC-1295 (no DAC) 100 mcg + GHRP-2 100 mcg + Ipamorelin 100 mcg per injection
- Reduce individual doses vs single-GHRP protocols; start with lower doses
- Twice daily
Storage and Handling
- Lyophilised: 2-8 degrees C; 24 months
- Reconstituted: 2-8 degrees C; use within 30 days
Key Research Benefits
Documented effects observed in preclinical and clinical studies on CJC-1295 & GHRP-2 & Ipamorelin Blend. See all Growth Hormone Secretagogues peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Subcutaneous injection on empty stomach. Reduced individual doses when all three combined.
Explore Further
Quick Reference
Research Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.